Clinical trials: HBP
Menopause, Hypertension
The Effects of Swimming on Elderly Women With Stage-2 Hypertension
Aging is associated with progressive decreases in arterial health and function as well as overall fitness. It is crucial to prevent or reduce the negative effects of aging on the vasculature and fitness components by implementing…
- Trial name
- NCT03546270
- Testing
- Swimming
- Volunteers
- 100 people
- Sponsor
- Pusan National University
Glaucoma, Angle-Closure
Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
- Trial name
- NCT03362931
- Testing
- XEN45
- Where
- 16 sites in Australia, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- Allergan
HIV/AIDS, Noncommunicable Diseases
Harambee: Integrated Community-based HIV/NCD Care & Microfinance Groups in Kenya
The objective of this project is to demonstrate the effectiveness and longer-term sustainability of a differentiated care delivery model for improving HIV treatment outcomes.
- Conditions
- HIV/AIDS, Noncommunicable Diseases, Hypertension, Diabetes
- Trial name
- NCT04417127
- Testing
- Integrated Community-Based (ICB) Care, Group-level Microfinance
- Where
- Kenya
- Volunteers
- 1,200 people
- Sponsor
- Brown University
Glaucoma
Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.
- Trial name
- Avastin (NCT00853073)
- Testing
- bevacizumab, balanced salt solution
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Wills Eye
Metabolic Diseases, Endocrine System Diseases
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk factors in the prediction of pre-clinical CVD.
- Conditions
- Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases
- Trial name
- NCT00935766
- Testing
- Omega-3
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Denver Health and Hospital Authority
Hypertension
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone
This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone
- Trial name
- NCT00777946
- Testing
- Aliskiren 300 mg, Aliskiren/Amlodipine 300/5 mg, Aliskiren/Amlodipine 300/10 mg
- Where
- 9 sites in Estonia, France and 7 more
- Volunteers
- 818 people
- Sponsor
- Novartis
Chronic Kidney Disease, Endothelial Dysfunction
Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation, blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become abnormally stimulated and accumulate in the…
- Conditions
- Chronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension
- Trial name
- NCT00428246
- Testing
- paricalcitol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Indiana University
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy of a Drug Delivery System in Glaucoma
Evaluation of the ocular safety and efficacy of a drug delivery system in open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01016691
- Testing
- High Dose Drug Device, Low Dose Drug Device, bimatoprost 0.03%
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Vistakon Pharmaceuticals
Hypertension, Portal
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also…
- Trial name
- NASH-CX (NCT02462967)
- Testing
- GR-MD-02
- Where
- 46 sites in United States
- Volunteers
- 162 people
- Sponsor
- Galectin Therapeutics Inc.
Metabolic Syndrome, Hypertension
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
This study will evaluate whether the mineralocorticoid receptor antagonist eplerenone, when compared to chlorthalidone plus potassium chloride, can improve cardiac MRI-derived myocardial perfusion reserve and fibrosis…
- Conditions
- Metabolic Syndrome, Hypertension, Overweight and Obesity
- Trial name
- NCT04519164
- Testing
- Eplerenone, Chlorthalidone with potassium chloride
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Brigham and Women's Hospital
Open-angle Glaucoma
Hydrus Microstent for Refractory Open-Angle Glaucoma
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma.
- Trial name
- SUMMIT (NCT03267134)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 20 sites in United States, Colombia and 3 more
- Volunteers
- 217 people
- Sponsor
- Ivantis, Inc.
Hypertension
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in…
- Trial name
- NCT00434967
- Testing
- Candesartan cilexetil, Hydrochlorothiazide, Candesartan/HCT 32/25 mg
- Where
- 27 sites in Belgium, Latvia and 4 more
- Volunteers
- 2,207 people
- Sponsor
- AstraZeneca
Primary Open Angle Glaucoma, Ocular Hypertension
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
- Trial name
- NCT00595101
- Testing
- PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle
- Where
- 13 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Bausch & Lomb Incorporated
Essential Hypertension
Helius in Hypertension-I: The UK Hypertension Registry
The purpose of this study is to demonstrate the use of a digital health offering in the management of persistent hypertension during chronic anti-hypertensive treatment.
- Trial name
- NCT02553512
- Testing
- Ingestible Sensor and Wearable Sensor
- Volunteers
- 151 people
- Sponsor
- Proteus Digital Health, Inc.
Liver Cirrhosis
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.
- Trial name
- NCT00592475
- Testing
- conivaptan
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cumberland Pharmaceuticals
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH)…
- Trial name
- NCT00796510
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 3 sites in United States, Romania and 1 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Hypertension
Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
This post-marketing surveillance study is designed to supplement the data on efficacy and tolerability of Micardis® and MicardisPlus® in patients at cardiovascular risk under general practice conditions.
- Trial name
- NCT01108796
- Where
- 182 sites in Slovenia
- Volunteers
- 1,856 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Hypertension
Renal and Hormonal Effects of Pioglitazone
This study examines the effects of pioglitazone on renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or hypertensive subjects.
- Trial name
- NCT01090752
- Testing
- Pioglitazone, Metformin
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University Hospital, Geneva
Blood Pressure
Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial
The purpose of this study is to compare the blood pressure lowering efficacy of a treatment regimen based on a dihydropyridine calcium-channel blocker combined with an angiotensin II type-1 receptor blocker with the recommended…
- Trial name
- NOAAH (NCT01030458)
- Testing
- amlodipine 5/10 mg per day plus valsartan 160 mg/day, hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day
- Where
- 7 sites in Cameroon, Côte d’Ivoire and 3 more
- Volunteers
- 183 people
- Sponsor
- KU Leuven
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.